Please provide your email address to receive an email when new articles are posted on . Mucosal melanoma — or melanoma in the mucous membranes — differs from cutaneous melanoma in its genesis, its ...

Scientists headed by a team at the University of Tokyo have identified a protein, known as podoplanin (PDPN), that is common to both human and canine mucosal melanoma, and which appears to mobilize ...

Although rare, mucosal melanoma in humans has a low survival rate. It has been difficult to investigate due to a lack of similar cancers in animals for study. Researchers explored a protein common to ...

"There are many other factors that could possibly contribute to better or worse prognosis for patients with mucosal melanoma, including mutational status of genes like BRAF." — Kathleen M. Mulligan, ...

Nemvaleukin alfa is an investigational, engineered fusion protein consisting of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain. The Food and Drug Administration (FDA) ...

Although rare, mucosal melanoma in humans has a low survival rate. It has been difficult to investigate due to a lack of similar cancers in animals for study. Researchers explored a protein common to ...

The FDA granted fast track designation to nemvaleukin alfa for treatment of mucosal melanoma. Nemvaleukin alfa (Alkermes) is an investigational engineered interleukin-2 variant immunotherapy. Source: ...

A phase 2 study evaluated meaningful activity from lifileucel for patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors. Lifileucel led to ...

Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma. Background: Mucosal melanoma is a rare but aggressive subtype of melanoma whose clinicopathologic ...

A retrospective study on the combination of a vascular endothelial growth factor receptor inhibitor plus programmed cell death-1 blockade added to evidence of efficacy in early trials. The combination ...

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. This is an ASCO Meeting ...

J.B. Ward's experience highlights the importance of self-advocacy in managing rare cancers, emphasizing the need for patients to seek multiple opinions and question medical advice. Mucosal melanoma is ...